Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Universal COVID-19 vaccine can be game-changer for developing countries like India, says GlobalData

The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.

10th Merck Bioforum India 2022 on Sept. 6-8

This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape

U.S. FDA grants emergency use authorization for Novavax COVID-19 vaccine

Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.

CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics

The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics

OPPI summit calls for collaboration across stakeholders

The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India

Covovax for teens get DCGI nod

It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D

Wockhardt and Serum Life Sciences UK partner to manufacture multiple vaccines in UK

The facility will produce 150 million vaccine doses per year